Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Dupixent also had been cleared for use in COPD in the European Union in early July, also for patients with uncontrolled ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

Regeneron's R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Read why I rate REGN ...

This summary of current health news includes FDA approvals for new drugs by Bristol Myers and GE HealthCare, public health ...

The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of ...

The US Food and Drug Administration FDA has approved French pharmaceutical company Sanofi Dupixent an anti-bronchitis drug ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.